

Mabion and Vaxine Enter into Memorandum of Understanding to Develop, Manufacture and Commercialize a COVID-19 Vaccine in the EU

Intended Polish-Australian collaboration will focus on clinical and regulatory support in Europe for leading Australian SARS-CoV-2 vaccine candidate currently in Phase I clinical testing

Konstantynów Łódzki, Poland, September 14, 2020 – Mabion S.A. (WSE:MAB), today announced that the company has entered into a Memorandum of Understanding (MoU) with Vaxine Pty Ltd. (“Vaxine”), an Australian biotechnology company, outlining further agreements for the purpose of concluding a collaboration for the joint development, production and commercialization in the EU of Vaxine's vaccine candidate against SARS-CoV-2, which is currently being evaluated in a Phase I clinical study. Upon completion of the prospective cooperation agreements, Mabion will become Vaxine’s partner to further develop, manufacture and commercialize the vaccine in the European Union, including Poland.

Vaxine is developing Covax-19[®], a potential COVID-19 vaccine that is based on a synthetic spike protein produced using an insect cell-based manufacturing process. Combining the spike protein with Vaxine’s proprietary Advax[™] adjuvant, Covax-19[®] induces antibody and T-cell immune responses against the co-administered antigen. In various animal models, Covax-19[®] has demonstrated to produce robust protection against COVID-19 infection.

In July of this year, Vaxine initiated a Phase I clinical trial with Covax-19[®] to evaluate the vaccine in 40 healthy volunteers. Based on the safety data from this initial study, regulators approved the further clinical development for the COVID-19 vaccine candidate. As part of the intended collaboration, the companies are planning to rapidly extend clinical evaluation into Europe, enabled by the European Medicines Agency (EMA)'s ongoing efforts to speed up regulatory procedures to ensure that decisions on the marketing authorization of safe and effective COVID-19 vaccines and therapeutics are made as quickly as possible.

“Vaxine’s interest in cooperating with Mabion is based on our excellence in the field of protein engineering, our expertise in clinical trial design and, above all, our capabilities in the production scale-up for the vaccine candidate. The development of an effective coronavirus vaccine has been the most important challenge for the global biotechnology industry since the start of the pandemic late last year. Protein engineering is Mabion's main area of scientific expertise and we value this opportunity to apply our knowledge to this great challenge.” **said Dr. Dirk Kreder, President of the Management Board of Mabion S.A.**

“The signed Memorandum of Understanding with Mabion and the prospective collaboration reflect the potential of Vaxine’s innovative pandemic vaccine technology that incorporates our unique Advax[™] adjuvant, designed to stimulate strong cellular and antibody immunity, while studies so far have demonstrated that our approach is safe and well-tolerated.” **said Professor Nikolai Petrovsky, Chairman and Research Director of Vaxine Pty Ltd.**

“The last few quarters have made the importance of controlled, qualified drug production clear to governments around the world. I am confident of Mabion’s competence in this area and look forward



to seeing this memorandum of understanding translate into a valuable collaboration between Mabion and Vaxine.” said **Dr. Maciej Wiczorek, Deputy Chairman of the Supervisory Board of Mabion S.A.**

“Vaxine demonstrated the potential of its Advax adjuvant™ in the swine flu pandemic, advancing its vaccine into clinical evaluation in less than three months. We believe that Mabion has an excellent technological background and an experienced team of scientists who will work together with the same sense of urgency in the fight against the coronavirus pandemic. At the same time, I would like to emphasize that the potential cooperation with Vaxine will not affect the development and commercialization of our lead candidate MabionCD20.” added **Dr. Dirk Kreder.**

The purpose of the memorandum between Mabion and Vaxine is to negotiate and conclude further agreements defining the terms and conditions of a cooperation, including development, production and commercialization conditions. Mabion stipulates, however, that the memorandum is intentional and non-binding, and its conclusion does not prejudice the conclusion of further agreements or cooperation of the parties in the future.

About the Company:

Mabion is the first Polish biotechnology company whose primary objective is to develop, manufacture and market biopharmaceutical drugs for several regulated markets.

The Company's lead project is MabionCD20. The Company is pursuing registration under the centralized procedure for all European markets in a partnership with Mylan - one of the largest pharmaceutical companies in the world. Another medium-term goal of the Company is to introduce MabionCD20 to the US market.

Since 2013, Mabion has been listed on the WSE's main market. The company is included in the mWIG40 index.

Find more information at: www.mabion.eu.

About Vaxine Pty Ltd:

Vaxine Pty Ltd was founded in 2002 and is an Australian biotechnology company focused on the development of innovative vaccines against seasonal and pandemic influenza, COVID-19, hepatitis B and Japanese encephalitis. For more information please visit: <http://vaxine.net/>

Press Contacts:

United States and Europe (exc. Poland)

Trophic Communications

Stephanie May or Eva Mulder

+49 89 238 877 30

mabion@trophic.eu

Poland

cc group

Michał Wierzchowski

phone: +48 531 613 067

e-mail: michal.wierzchowski@ccgroup.pl